N- and O-glycome analysis of serum and urine from bladder cancer patients using a high-throughput glycoblotting method

Amano, Motoi Takeuchi Maho

doi:10.4172/2153-0637.1000108

Cited by 7 publications

(16 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown that differences in serum N -glycan profiles between diseased and benign states analyzing high-throughput, comprehensive and quantitative N -glycomics may be useful in the diagnosis or prognosis of diseases [ 11 , 12 , 13 , 14 , 19 ]. A few studies have investigated the use of serum N -glycans as diagnostic markers for UC, including UTUC [ 13 , 19 ]. Although these reports showed that the levels of highly branched sialylated N -glycans ( m / z 2890, 3560, 3865) were increased in the sera of patients with bladder cancer [ 13 , 19 ], they did not identify carrier proteins of aberrant N -glycosylation.…”

Section: Discussionmentioning

confidence: 99%

“…A few studies have investigated the use of serum N -glycans as diagnostic markers for UC, including UTUC [ 13 , 19 ]. Although these reports showed that the levels of highly branched sialylated N -glycans ( m / z 2890, 3560, 3865) were increased in the sera of patients with bladder cancer [ 13 , 19 ], they did not identify carrier proteins of aberrant N -glycosylation. Furthermore, these highly branched sialylated N -glycans in serum were also significantly upregulated in plural cancer, such as prostate or kidney cancer [ 11 , 12 ].…”

Section: Discussionmentioning

confidence: 99%

“…Glycosylation is a common post-translational modification that has an important role in various biological functions. Previously, our group demonstrated that high-throughput, comprehensive and quantitative N -glycomics based on the glycoblotting method combined with mass spectrometry is a promising way to screen glycans for use as diagnostic and prognostic markers of several cancer [ 11 , 12 , 13 , 14 , 15 ]. Recently, the evaluation of glycosylation profile is an innovative topic in different cancer types, especially in immunotherapeutic targets, as like as PD-L1 [ 16 , 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

Tanaka

Yoneyama

Noro

et al. 2017

IJMS

View full text Add to dashboard Cite

The aim of this study to determine whether the aberrant N-glycosylated serum immunoglobulins (Igs) can be applied as a diagnostic marker of urothelial carcinoma (UC). Between 2009 and 2016, we randomly obtained serum available from 237 UC and also 96 prostate cancer as other cancer controls from our serum bank and also obtained—from 339 healthy volunteers (HV)—controls obtained from community-dwelling volunteers in Iwaki Health Promotion Project. A total of 32 types of N-glycan levels on Igs were determined by high-throughput N-glycomics and analyzed by multivariable discriminant analysis. We found five UC-associated aberrant N-glycans changes on Igs and also found that asialo-bisecting GlcNAc type N-glycan on Igs were significantly accumulated in UC patients. The diagnostic N-glycan Score (dNGScore) established by combination of five N-glycans on Igs discriminated UC patients from HV and prostate cancer (PC) patients with 92.8% sensitivity and 97.2% specificity. The area under the curve (AUC) for of the dNGScore was 0.969 for UC detection that was much superior to that of urine cytology (AUC, 0.707) and hematuria (AUC, 0.892). Furthermore, dNGScore can detect hematuria and urine cytology negative patients. The dNGscore based on aberrant N-glycosylation signatures of Igs were found to be promising diagnostic biomarkers of UCs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

Tanaka

Yoneyama

Noro

et al. 2017

IJMS

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

Tanaka¹,

Yoneyama²,

Noro³

et al. 2018

European Urology Supplements

View full text Add to dashboard Cite

Abstract:The aim of this study to determine whether the aberrant N-glycosylated serum immunoglobulins (Igs) can be applied as a diagnostic marker of urothelial carcinoma (UC). Between 2009 and 2016, we randomly obtained serum available from 237 UC and also 96 prostate cancer as other cancer controls from our serum bank and also obtained-from 339 healthy volunteers (HV)-controls obtained from community-dwelling volunteers in Iwaki Health Promotion Project. A total of 32 types of N-glycan levels on Igs were determined by high-throughput N-glycomics and analyzed by multivariable discriminant analysis. We found five UC-associated aberrant N-glycans changes on Igs and also found that asialo-bisecting GlcNAc type N-glycan on Igs were significantly accumulated in UC patients. The diagnostic N-glycan Score (dNGScore) established by combination of five N-glycans on Igs discriminated UC patients from HV and prostate cancer (PC) patients with 92.8% sensitivity and 97.2% specificity. The area under the curve (AUC) for of the dNGScore was 0.969 for UC detection that was much superior to that of urine cytology (AUC, 0.707) and hematuria (AUC, 0.892). Furthermore, dNGScore can detect hematuria and urine cytology negative patients. The dNGscore based on aberrant N-glycosylation signatures of Igs were found to be promising diagnostic biomarkers of UCs.

show abstract

N‐glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas

et al. 2021

View full text Add to dashboard Cite

Discriminating between urothelial carcinoma (UC), including bladder cancer (BCa) and upper urinary tract UC (UTUC), is often challenging. Thus, the current study evaluated the diagnostic performance of N‐glycosylation signatures of immunoglobulins (Igs) for detecting UC, including BCa and UTUC. N‐glycosylation signatures of Igs from serum samples of the training cohort, including 104 BCa, 68 UTUC, 10 urinary tract infection, and 5 cystitis cases, as well as 62 healthy volunteers, were measured retrospectively using automated capillary‐electrophoresis‐based N‐glycomics. UTUC or BCa scores were then established through discriminant analysis using N‐glycan signatures of Igs. Diagnostic performance was evaluated using the area under receiver operating characteristics curve (AUC) and decision curve analyses (DCA). Our result showed that BCa and UTUC scores for discriminating BCa (AUC: 0.977) and UTUC (AUC: 0.867), respectively, provided significantly better clinical performance compared to urine cytology, gross hematuria, or clinical T1 cases. DCA revealed that adding BCa and UTUC scores to gross hematuria status was the best combination for detecting UC and avoiding the need for more intervention without overlooking UC (risk threshold: 13%–93%). The UC nomogram based on the combination of gross hematuria, UTUC score, and BCa score could detect UC with an AUC of 0.891, indicating significantly better performance compared to gross hematuria status in the validation cohort (251 patients). The limitations of this study include its small sample size and retrospective nature. The UC nomogram based on gross hematuria and N‐glycosylation signatures of Igs can be a promising approach for the diagnosis of UC.

show abstract

N- and O-glycome analysis of serum and urine from bladder cancer patients using a high-throughput glycoblotting method

Cited by 7 publications

References 51 publications

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

Aberrant N-Glycosylation Profile of Serum Immunoglobulins is a Diagnostic Biomarker of Urothelial Carcinomas

Aberrant N-glycosylation profile of serum immunoglobulins is a diagnostic biomarker of urothelial carcinomas

N‐glycan signature of serum immunoglobulins as a diagnostic biomarker of urothelial carcinomas

Contact Info

Product

Resources

About